Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model.
Ramakrishnan A, Joseph SS, Reynolds ND, Poncet D, Maciel M Jr, Nunez G, Espinoza N, Nieto M, Castillo R, Royal JM, Poole S, McVeigh A, Rollenhagen JE, Heinrichs J, Prouty MG, Simons MP, Renauld-Mongénie G, Savarino SJ. Ramakrishnan A, et al. Among authors: joseph ss. Vaccine. 2021 Jan 15;39(3):487-494. doi: 10.1016/j.vaccine.2020.12.034. Epub 2020 Dec 21. Vaccine. 2021. PMID: 33357957
Refinement of the CS6-expressing enterotoxigenic Escherichia coli strain B7A human challenge model: A randomized trial.
Talaat KR, Porter CK, Jaep KM, Duplessis CA, Gutierrez RL, Maciel M Jr, Adjoodani B, Feijoo B, Chakraborty S, Brubaker J, Trop SA, Riddle MS, Joseph SS, Bourgeois AL, Prouty MG. Talaat KR, et al. Among authors: joseph ss. PLoS One. 2020 Dec 2;15(12):e0239888. doi: 10.1371/journal.pone.0239888. eCollection 2020. PLoS One. 2020. PMID: 33264302 Free PMC article. Clinical Trial.
Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenic Escherichia coli as a prophylactic against diarrhea.
Talaat KR, Porter CK, Bourgeois AL, Lee TK, Duplessis CA, Maciel M Jr, Gutierrez RL, DeNearing B, Adjoodani B, Adkinson R, Testa KJ, Feijoo B, Alcala AN, Brubaker J, Beselman A, Chakraborty S, Sack D, Halpern J, Trop S, Wu H, Jiao J, Sullivan E, Riddle MS, Joseph SS, Poole ST, Prouty MG. Talaat KR, et al. Among authors: joseph ss. Gut Microbes. 2020 Nov 9;12(1):1732852. doi: 10.1080/19490976.2020.1732852. Epub 2020 Mar 13. Gut Microbes. 2020. PMID: 32167011 Free PMC article. Clinical Trial.
Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.
Douglas RS, Kossler AL, Abrams J, Briceño CA, Gay D, Harrison A, Lee M, Nguyen J, Joseph SS, Schlachter D, Tan J, Lynch J, Oliver L, Perry R, Ugradar S. Douglas RS, et al. Among authors: joseph ss. J Neuroophthalmol. 2022 Sep 1;42(3):334-339. doi: 10.1097/WNO.0000000000001560. Epub 2022 Mar 24. J Neuroophthalmol. 2022. PMID: 35421877 Free PMC article.
Endoscopic Technique for Sural Nerve Graft Harvest with Novel Device.
Joseph AW, Nagappan K, Joseph SS. Joseph AW, et al. Among authors: joseph ss. Facial Plast Surg Aesthet Med. 2022 Mar-Apr;24(2):124-125. doi: 10.1089/fpsam.2021.0341. Epub 2022 Jan 18. Facial Plast Surg Aesthet Med. 2022. PMID: 35049382 No abstract available.
Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
Teo HM, Smith TJ, Joseph SS. Teo HM, et al. Among authors: joseph ss. Ther Clin Risk Manag. 2021 Nov 25;17:1219-1230. doi: 10.2147/TCRM.S303057. eCollection 2021. Ther Clin Risk Manag. 2021. PMID: 34858025 Free PMC article. Review.
48 results